Table 1 OpenArray™ study patient characteristics
From: Altered Extracellular Vesicle MicroRNA Expression in Ischemic Stroke and Small Vessel Disease
Non-Stroke | Stroke | p (Fisher’s test) | ||||
|---|---|---|---|---|---|---|
n | % | n | % | |||
Age and gender | n | 10 | 29 | NA | ||
Male, % (n) | 7 | 70.0 | 22 | 75.9 | 0.696 | |
Median age [IQR] | 70.0 [62.8–84.0] | – | 73.0 [60.5–79.5] | – | 0.544✞ | |
Risk factors for ischaemic stroke | Hypertension, % (n) | 7 | 70.0 | 15 | 51.7 | 0.464 |
Atrial fibrillation, % (n) | 3 | 30.0 | 5 | 17.2 | 0.399 | |
Diabetes (type 1 or 2), % (n) | 3 | 30.0 | 7 | 24.1 | 0.696 | |
Hyperlipidaemia, % (n) | 3 | 30.0 | 9 | 31.0 | 1.000 | |
Peripheral vascular disease, % (n) | 0 | 0.0 | 0 | 0.0 | 1.000 | |
Smoker, % (n) | 3 | 30.0 | 9 | 31.0 | 1.000 | |
Ex smoker, % (n) | 3 | 30.0 | 6 | 20.7 | 0.669 | |
Previous stroke, % (n) | 2 | 20.0 | 4 | 13.8 | 0.636 | |
Family history, % (n) | 1 | 10.0 | 4 | 13.8 | 1.000 | |
Medication | Recombinant tissue plasminogen activator, % (n) | – | – | 10 | 34.5 | NA |
ACE inhibitor, % (n) | 4 | 40.0 | 5 | 17.2 | 0.197 | |
Alpha blocker, % (n) | 1 | 10.0 | 0 | 0.0 | 0.256 | |
Anticoagulant, % (n) | 1 | 10.0 | 1 | 3.4 | 0.452 | |
Antiplatelet, % (n) | 6 | 60.0 | 8 | 27.6 | 0.124 | |
ARB, % (n) | 0 | 0.0 | 3 | 10.3 | 0.556 | |
Beta blocker, % (n) | 4 | 40.0 | 9 | 31.0 | 0.704 | |
Blood pressure treatment, % (n) | 7 | 70.0 | 15 | 51.7 | 0.464 | |
CCB, % (n) | 4 | 40.0 | 3 | 10.3 | 0.057 | |
Loop diuretic, % (n) | 3 | 30.0 | 4 | 13.8 | 0.344 | |
Oral hypoglycaemic drugs, % (n) | 2 | 20.0 | 2 | 6.9 | 0.267 | |
Spironolactone, % (n) | 1 | 10.0 | 1 | 3.4 | 0.452 | |
Statin, % (n) | 6 | 60.0 | 13 | 44.8 | 0.480 | |
Thiazide, % (n) | 2 | 20.0 | 2 | 6.9 | 0.267 | |
Stroke status | Median baseline NIHSS [IQR] | 1 [0–5.5] | – | 4 [2.5–11] | – | 0.054♦ |